AstraZeneca Antibody Kit Will Save Those Who Cannot Be Vaccinated From Covid

AstraZeneca announced that it has filed applications in various countries to register a new type of SARS-CoV-2 drug called AZD7442. It is based on antibodies collected from the first COVID-19 patients a year and a half ago. They were used to obtain effective monoclonal antibodies, which have already passed clinical trials.

Attention to antibody treatment arose against the background of the failed situation with vaccination both in the world as a whole and in individual countries. It turned out that mankind will not be able to achieve collective immunity in principle because of a variety of political, social, religious and other disagreements. But even worse, there are a number of patients with chronic diseases, extremely low immunity and undergoing immunosuppressive treatment for other diseases – their bodies will not tolerate contact with the vaccine.

The AZD7442 trial, dubbed Provent, followed 5,000 immunocompromised patients for six months. No cases of severe disease were identified, although many were infected with covid. The trial concluded that AZD7442 reduced the risks of developing symptomatic COVID-19 by 77%. The antibodies don’t cure people, but they take over most of the fight against the virus, resulting in a milder form of the disease. This is a long-awaited chance for immunocompromised people to get protection against the infection.